Recent Use of Pediatric Extrapolation in Pediatric Drug Development in US

• Published in: Journal of biopharmaceutical statistics 2023-11, Vol.33 (6), p.681-695
• Main Authors: Ye, Jingjing, Zhang, Vickie, Strimenopoulou, Foteini, Zhao, Yihua, Pan, Haitao, Shabbout, Mayadah, Gamalo, Margaret
• Format: Article
• Language: English
• Subjects: Child; Drug Approval; Drug Development; efficacy; extrapolation; Humans; Pediatric label; Pharmaceutical Preparations; safety; source and target population; United States; United States Food and Drug Administration
• ISSN: 1054-3406; 1520-5711
• DOI: 10.1080/10543406.2023.2170407

The regulatory standards of the United States Food and Drug Administration (FDA) require substantial evidence of effectiveness from adequate and well-controlled trials, for drugs developed in both adults and children. However, when scientifically justified, relying on extrapolation may be acceptable. Historically, the FDA's extrapolation approach was based on draft guidance published in 2014, which introduced the categories of full, partial, and no extrapolation. The European Medicines Agency (EMA) took a different view on pediatric extrapolation. To better understand the use of extrapolation to support pediatric drug development and approval, we reviewed the pediatric labeling changes published by the FDA, focusing on the labeling updates between 1/1/2015 and 7/31/2021, the period where the extrapolation approach is in transition to harmonize with the EMA. Within this time window, among the 265 drugs and biological products with pediatric labeling changes, 169 (63.8%) were identified where extrapolation was used. This includes 64 (24.2%) labeling changes, where full extrapolation was used, and 105 (39.6%) labeling changes, where partial extrapolation was used. The major disease areas that extrapolation was used include neuroscience (40/53, 75.5%) and infectious disease (20/28, 71.4%). The extrapolation approach was identified in terms of source population beyond the use of adult as well as extrapolation from clinical trials conducted in the same drug class. The use of extrapolation increased the rates of new and expanded pediatric indication in the period. This review gives the most recent landscape of pediatric labeling changes using extrapolation. With the released ICH (International Council for Harmonization) E11A guidance in April 2022, the paper also provides insights for future pediatric drug development programs.